Company Overview and News

1
Walkabout Resources share spike attracts ASX speeding ticket

2018-05-11 proactiveinvestors.com.au
Walkabout Resources Ltd’s (ASX:WKT) shares have been on a tear, rising from a close of 8.3 cents on Thursday to an intraday high of 10.5 cents today, prompting the ASX to issue a speeding ticket.
DRLDF DNA.WT.A DRRLF WKT DALR DNA

1
Dalradian announces a 46% increase in Measured & Indicated gold ounces and a 32% increase in Inferred gold ounces in new Mineral Resource Statement

2018-05-10 globenewswire
TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") announces an updated mineral resource statement on the Curraghinalt gold deposit in Northern Ireland (“Mineral Resource Statement”), including a 46% increase in gold ounces contained in the Measured and Indicated (“M&I”) categories and a 32% increase in Inferred gold ounces compared to the 2016 resource.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Dalradian intersects 1.54 metres at 61.49 g/t gold from drilling at Curraghinalt

2018-05-01 globenewswire
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) is pleased to report results from 13 step-out drill holes and 30 infill drill holes at the Curraghinalt gold deposit in Northern Ireland.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Walkabout Resources to fly survey over Northern Ireland cobalt-copper-silver targets

2018-04-11 proactiveinvestors.com.au
Walkabout Resources Ltd (ASX:WKT) will fly an airborne electromagnetic (EM) survey over target areas of the Slieve Gallion cobalt-copper-silver joint venture licence area in Northern Ireland.
DRLDF DNA.WT.A DRRLF WKT DALR DNA

1
Walkabout Resources set to unlock lithium, cobalt, gold and graphite opportunities

2018-03-27 proactiveinvestors.com.au
Walkabout Resources Ltd (ASX:WKT) is continuing to focus on lithium exploration in Namibia along with an active cobalt exploration program in Northern Ireland.
DRLDF DNA.WT.A LMI DRRLF WKT DALR DNA

1
Dalradian reports 2017 results with year-end cash of $138 million

2018-03-19 globenewswire
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) announces results for the three months and year ended December 31, 2017, including closing cash and cash equivalents of $138 million1.
DRLDF DNA.WT.A DRRLF DALR DNA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...